SAN FRANCISCO, April 10, 2012 /PRNewswire/ -- Medizone International, Inc. (MZEI:OB) (MZEI:QB) announced today that the first production unit of its AsepticSure disinfection technology has been successfully completed by its manufacturing partner, SMTC Corporation (NASDAQ:SMTX).
Following performance confirmation testing of the initial unit, four additional units will immediately be manufactured for independent validation testing and subsequently placed into commercial service. The first five production units are expected to be delivered to Medizone by month's end.
"Our peer reviewed article in the AJIC and more recent recognition in Geneva for Innovation Excellence marked the beginning of a series of amazing achievements for Medizone," stated Dr Michael Shannon, President and Director of Medical Affairs.
"A combination of scientific, developmental and technological advancements made by the company over the past 12 months has seen us arrive at the brink of an exciting new era in Medizone's history."I have no doubt whatsoever that AsepticSure is poised to become the gold standard for hospital disinfection," said Shannon. Medizone International's Chairman and CEO, Edwin Marshall commented: "In addition to successfully initiating production, we're pleased to announce that Health Canada recently informed us that they will not regulate AsepticSure as either a medical device or disinfectant. Additionally, they will not require a new DIN (drug identification number) for the AsepticSure catalyst. "The Company views this ruling by Health Canada in the most favorable light. It means that following standard validation testing of the initial production units over the coming 4 weeks, the Company may then begin commercial sales of AsepticSure in Canada. "For Medizone to successfully develop and launch such a superior, fast-acting (green) disinfection technology capable of consistently producing 100% bacterial kills on both hard and soft surfaces without leaving any residual residue... it's an amazing achievement. Our R&D, science, regulatory, patent and production teams have done an outstanding job. I couldn't be more proud of them." In related news, Medizone's regulatory team has also submitted a Request for Designation in the US, to the FDA. For press information on Medizone International, please contact:
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV